Royalty Pharma Plc · NASDAQ:RPRX
Royalty Pharma — Investor Presentation (September 2024)
6 slides from Royalty Pharma's investor presentation, September 2024
Slide 1: Royalty Pharma
ROYALTY PHARMA
Slide 2: Yorvipath royalty acquisition, September 2024
royalty acquisition September 2024 The Yorvipath logo is a trademark owned by Ascendis Pharma
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or
Slide 4: Yorvipath – addressing unmet need in hypoparathyroidism
Yorvipath – addressing unmet need in hypoparathyroidism 1 2 3 FDA approved therapy for Unmet need for effective Significant commercial hypoparathyroidism and convenient treatments opportunity for Yorvipath Yorvipath is the only FDA approved Vitamin D and calcium alleviate symptoms ~70,000-90,000 peo
Slide 5: Yorvipath – only FDA approved therapy for hypoparathyroidism
Yorvipath – only FDA approved therapy for hypoparathyroidism Yorvipath U.S. consensus sales projections(2) ($ in millions) • Acquired a synthetic royalty on Ascendis’ Yorvipath for adults with hypoparathyroidism ▪ $150 million upfront payment ▪ Entitled to 3% royalty on sales in the U.S. ▪ Royalty p
Slide 6: Yorvipath – significant U.S. commercial opportunity
Yorvipath – significant U.S. commercial opportunity ~6,000 HCPs diagnose and treat patients; majority of targets in endocrinology and represent ~80% of opportunity Total US prevalence(1) Newly diagnosed(1) PTH experienced(1) ~70,000-90,000 ~3,000 annually ~4,000-5,000 Current treatment Post-surgical
Royalty Pharma — Investor Presentation (September 2024) on 6ix